Marianna M. Henry

Inhaled versus systemic antibiotics and airway inflammation in children with cystic fibrosis and Pseudomonas.

Inhaled tobramycin has been shown to transiently clear Pseudomonas from lower airways in early cystic fibrosis (CF), but does not markedly reduce lung inflammation, a key factor in disease progression.

Pharmacokinetics of amiloride after inhalation and oral administration in adolescents and adults with cystic fibrosis

Study Objective. To compare the pharmacokinetics and systemic exposure of nebulized and oral amiloride in adolescents and adults with mild to moderate cystic fibrosis (CF).

Therapeutic challenges posed by critical drug–drug interactions in cystic fibrosis

This review seeks to re‐introduce cystic fibrosis (CF) clinicians to the pharmacology of drug–drug interactions among medications commonly used in CF and provide a framework for understanding these interactions among medications outside the scope of this discussion. We here focus on drugs impacted by the cytochrome P‐450 (CYP450) enzyme system and on interactions involving antimicrobials, psychotropic medications, and cystic fibrosis transmembrane conductance regulator (CFTR) modulators. Particular attention is needed when prescribing rifampin, azole antifungals and the CFTR modulators, ivacaftor, and lumacaftor/ivacaftor, in combination with other medications. The complexities of these interactions provide a strong rationale for case management by pharmacists and pharmacologists as a routine part of CF care. Pediatr Pulmonol. 2016;51:S61–S70.

A quantitative study of the development of interalveolar pores in the postnatal mouse

Quantitative analysis of regional interalveolar pore development in the lungs of C3Hf/He mice was performed using scanning electron microscopy. Lungs of male mice ages 7, 10, 14, 21, 28, and 56 days were studied following intratracheal fixation. Interalveolar pores were counted in subpleural, midzonal, and peribronchiolar regions. Interalveolar pores were rarely observed in mice ages 7, 10, and 14 days but appeared abruptly at age 21 days throughout the lung. The number of interalveolar pores increased 2-3 fold from ages 21 to 56 days. By age 28 days and thereafter interalveolar pores were more numerous in subpleural alveoli than in midzonal or peribronchiolar alveoli. We conclude that interalveolar pores appear diffusely in the lungs of mice during the third postnatal week and that regional differences in the number of interalveolar pores are established by age 28 days.